Gastric cancer represents the fourth most common cancer and second leading cause of cancer deaths worldwide. The 5-year relative survival rate of gastric cancer is 20-30%. Curative treatment of gastric cancer requires complete surgical removal of tumor tissue; however, many patients will have a recurrence after surgery and die within a few months or years. There is no effective therapy for advanced stage gastric cancer. The objective of the project with Yonsei University Health System (YUHS) an MDACC sister Institution is to use next-generation deep sequencing of patient gastric tumors to identify novel targets for the development of new agents to treat gastric cancer, and to develop lead compounds for at least two targets in the two year life time of the project. The hypothesis upon which the work is based is that "next generation sequencing of gastric cancer from Asia and the US will yield new targets for developing drugs to treat gastric cancer".